Основная статистика
| CIK | 885306 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cynosure, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| February 9, 2018 |
CYNO / Cynosure, Inc. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CYNOSURE INC-A (Name of Issuer) Common Stock (Title of Class of Securities) 232577205 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| April 6, 2017 |
15-12G 1 a17-6845171512g.htm 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-51623 CYNOSURE, INC. (Exact name of |
|
| March 23, 2017 |
Exhibit 3.2 EXHIBIT 3.2 BY-LAWS of CYNOSURE, INC. dated as of March 21, 2017 TABLE OF CONTENTS ARTICLE I OFFICES SECTION 1. REGISTERED OFFICE 1 SECTION 2. OTHER OFFICES 1 ARTICLE II MEETINGS OF STOCKHOLDERS SECTION 1. ANNUAL MEETINGS 1 SECTION 2. SPECIAL MEETINGS 1 SECTION 3. VOTING 1 SECTION 4. QUORUM 2 SECTION 5. NOTICE OF MEETINGS 2 SECTION 6. ACTION WITHOUT MEETING 2 ARTICLE III DIRECTORS SECT |
|
| March 23, 2017 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION CYNOSURE, INC. ARTICLE I Exhibit 3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CYNOSURE, INC. ARTICLE I The name of the corporation is Cynosure, Inc. (the ?Corporation?). ARTICLE II The address, including street, number, city, and county, of the registered office of the Corporation in the State of Delaware is c/o the Corporation Trust Company, Corporation Trust Center, 1209 Orange Street, City of Wi |
|
| March 23, 2017 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2017 CYNOSURE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 22, 2017 |
S-8 POS 1 d326335ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on March 22, 2017 Registration No. 333-189797 Registration No. 333-186398 Registration No. 333-179452 Registration No. 333-171984 Registration No. 333-164569 Registration No. 333-157945 Registration No. 333-130237 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment |
|
| March 22, 2017 |
S-8 POS As filed with the Securities and Exchange Commission on March 22, 2017 Registration No. |
|
| March 22, 2017 |
S-8 POS 1 d326335ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on March 22, 2017 Registration No. 333-189797 Registration No. 333-186398 Registration No. 333-179452 Registration No. 333-171984 Registration No. 333-164569 Registration No. 333-157945 Registration No. 333-130237 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment |
|
| March 22, 2017 |
S-8 POS 1 d326335ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on March 22, 2017 Registration No. 333-189797 Registration No. 333-186398 Registration No. 333-179452 Registration No. 333-171984 Registration No. 333-164569 Registration No. 333-157945 Registration No. 333-130237 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment |
|
| March 22, 2017 |
S-8 POS 1 d326335ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on March 22, 2017 Registration No. 333-189797 Registration No. 333-186398 Registration No. 333-179452 Registration No. 333-171984 Registration No. 333-164569 Registration No. 333-157945 Registration No. 333-130237 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment |
|
| March 22, 2017 |
S-8 POS 1 d326335ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on March 22, 2017 Registration No. 333-189797 Registration No. 333-186398 Registration No. 333-179452 Registration No. 333-171984 Registration No. 333-164569 Registration No. 333-157945 Registration No. 333-130237 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment |
|
| March 22, 2017 |
S-8 POS 1 d326335ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on March 22, 2017 Registration No. 333-189797 Registration No. 333-186398 Registration No. 333-179452 Registration No. 333-171984 Registration No. 333-164569 Registration No. 333-157945 Registration No. 333-130237 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment |
|
| March 22, 2017 |
POS AM 1 d326340dposam.htm POS AM As filed with the Securities and Exchange Commission on March 22, 2017 Registration No. 333-184216 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: FORM S-3 REGISTRATION STATEMENT NO. 333-184216 UNDER THE SECURITIES ACT OF 1933 CYNOSURE, INC. (Exact name of registrant as specified in its charter) Delaware 0 |
|
| March 22, 2017 |
SC 14D9/A 1 d326329dsc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 7) CYNOSURE, INC. (Name of Subject Company) CYNOSURE, INC. (Name of Person Filing Statement) Class A Common Stock, par value $0.001 per share |
|
| March 22, 2017 |
SC TO-T/A 1 a17-684515sctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 7) CYNOSURE, INC. (Name of Subject Company) MINUTEMAN MERGER SUB, INC. (Offeror) HOLOGIC, INC. (Names of Filing Persons) CLASS A COMMON STOCK, $0. |
|
| March 22, 2017 |
Exhibit (a)(1)(J) Hologic Completes Acquisition of Cynosure ? Transaction Provides Entry into Large, Fast-Growing Medical Aesthetics Market, Boosts Hologic?s Growth Rate ? MARLBOROUGH, Mass. |
|
| March 21, 2017 |
10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 20, 2017 |
SC 14D9/A 1 d342985dsc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 6) CYNOSURE, INC. (Name of Subject Company) CYNOSURE, INC. (Name of Person Filing Statement) Class A Common Stock, par value $0.001 per share |
|
| March 20, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 6) CYNOSURE, INC. (Name of Subject Company) MINUTEMAN MERGER SUB, INC. (Offeror) HOLOGIC, INC. (Names of Filing Persons) CLASS A COMMON STOCK, $0.001 PAR VALUE (Title of Class of Securities |
|
| March 10, 2017 |
SC 14D9/A 1 d357408dsc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 5) CYNOSURE, INC. (Name of Subject Company) CYNOSURE, INC. (Name of Person Filing Statement) Class A Common Stock, par value $0.001 per share |
|
| March 10, 2017 |
SC TO-T/A 1 a17-684513sctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) CYNOSURE, INC. (Name of Subject Company) MINUTEMAN MERGER SUB, INC. (Offeror) HOLOGIC, INC. (Names of Filing Persons) CLASS A COMMON STOCK, $0. |
|
| March 9, 2017 |
SC 14D9/A 1 d353830dsc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 4) CYNOSURE, INC. (Name of Subject Company) CYNOSURE, INC. (Name of Person Filing Statement) Class A Common Stock, par value $0.001 per share |
|
| March 9, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) CYNOSURE, INC. (Name of Subject Company) MINUTEMAN MERGER SUB, INC. (Offeror) HOLOGIC, INC. (Names of Filing Persons) CLASS A COMMON STOCK, $0.001 PAR VALUE (Title of Class of Securities |
|
| March 3, 2017 |
SC 14D9/A 1 d358252dsc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) CYNOSURE, INC. (Name of Subject Company) CYNOSURE, INC. (Name of Person Filing Statement) Class A Common Stock, par value $0.001 per share |
|
| March 3, 2017 |
SC TO-T/A 1 a17-684511sctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) CYNOSURE, INC. (Name of Subject Company) MINUTEMAN MERGER SUB, INC. (Offeror) HOLOGIC, INC. (Names of Filing Persons) CLASS A COMMON STOCK, $0. |
|
| February 28, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) CYNOSURE, INC. (Name of Subject Company) CYNOSURE, INC. (Name of Person Filing Statement) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 232577205 |
|
| February 28, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) CYNOSURE, INC. (Name of Subject Company) MINUTEMAN MERGER SUB, INC. (Offeror) HOLOGIC, INC. (Names of Filing Persons) CLASS A COMMON STOCK, $0.001 PAR VALUE (Title of Class of Securities |
|
| February 28, 2017 |
Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 28, 2017 |
SUBSIDIARIES OF THE REGISTRANT EX-21.1 SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 SUBSIDIARY JURISDICTION OF INCORPORATION S.A.R.L. Cynosure France France Cynosure Maroc SARL France Cynosure GmbH Germany Cynosure K.K. Japan Cynosure UK LTD United Kingdom Cynosure Spain S.L. Spain Cynosure Securities Corporation United States Suzhou Cynosure Medical Devices Company Ltd. China Cynosure Mexico, S de R.L. de C.V. Mexico Cynosure K |
|
| February 28, 2017 |
WITNESSETH ARTICLE I 1.0 Premises EX-10.31 Exhibit 10.31 LEASE THIS INDENTURE OF LEASE made the 18th day of January, 2017, by and between Ryan Development LLC, a Massachusetts limited liability company with a principal place of business at 4 Lan Drive, Westford, Massachusetts 01886 (hereinafter referred to as “Landlord”), of the one part; Cynosure, Inc. a Delaware corporation having a principal place of business at 5 Carlisle Road |
|
| February 24, 2017 |
SC 14D9/A 1 d379313dsc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) CYNOSURE, INC. (Name of Subject Company) CYNOSURE, INC. (Name of Person Filing Statement) Class A Common Stock, par value $0.001 per share |
|
| February 24, 2017 |
Exhibit (a)(1)(I) Notice of Offer to Purchase for Cash All Outstanding Shares of Class A Common Stock of CYNOSURE, INC. |
|
| February 24, 2017 |
SC TO-T/A 1 a17-68459sctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) CYNOSURE, INC. (Name of Subject Company) MINUTEMAN MERGER SUB, INC. (Offeror) HOLOGIC, INC. (Names of Filing Persons) CLASS A COMMON STOCK, $0.0 |
|
| February 22, 2017 |
8-K 1 d351796d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2017 CYNOSURE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporatio |
|
| February 22, 2017 |
EX-99.e.18 Exhibit (e)(18) Cynosure, Inc. FROM: Tom Robinson SUBJECT: Retention Bonus Payment DATE: February 21, 2017 Dear Mike, As you know, on February 14, 2017, Cynosure, Inc. (the ?Company?) and Hologic, Inc. (?Hologic?) entered into a definitive agreement for Hologic to acquire all of the outstanding equity of the Company. In connection with the transaction, the Company has established a cash |
|
| February 22, 2017 |
SC 14D9 1 d328162dsc14d9.htm SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CYNOSURE, INC. (Name of Subject Company) CYNOSURE, INC. (Name of Person Filing Statement) Class A Common Stock, par value $0.001 per share (Tit |
|
| February 22, 2017 |
EX-99.e.19 Exhibit (e)(19) Cynosure, Inc. FROM: Tom Robinson SUBJECT: Retention Bonus Payment DATE: February 21, 2017 Dear Steve, As you know, on February 14, 2017, Cynosure, Inc. (the ?Company?) and Hologic, Inc. (?Hologic?) entered into a definitive agreement for Hologic to acquire all of the outstanding equity of the Company. In connection with the transaction, the Company has established a cas |
|
| February 22, 2017 |
EX-99.a.8 Exhibit (a)(8) February 22, 2017 Dear Stockholder: I am pleased to inform you that, on February 14, 2017, Cynosure, Inc. (?Cynosure?) entered into an Agreement and Plan of Merger (the ?Merger Agreement?) with Hologic, Inc. (?Parent?) and Minuteman Merger Sub, Inc. (?Purchaser?), a wholly-owned subsidiary of Parent. In accordance with the Merger Agreement, on February 22, 2017, Purchaser |
|
| February 22, 2017 |
QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(C) Offer To Purchase For Cash All Outstanding Shares of Class A Common Stock of CYNOSURE, INC. |
|
| February 22, 2017 |
SC TO-T 1 a2231000zscto-t.htm SC TO-T QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 CYNOSURE, INC. (Name of Subject Company) MINUTEMAN MERGER SUB, INC. (Offeror) HOLOGIC, INC. (Names o |
|
| February 22, 2017 |
QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Class A Common Stock of CYNOSURE, INC. |
|
| February 22, 2017 |
QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(H) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). |
|
| February 22, 2017 |
Use these links to rapidly review the document TABLE OF CONTENTS Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Class A Common Stock of Cynosure, Inc. |
|
| February 22, 2017 |
QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(D) Offer To Purchase For Cash All Outstanding Shares of Class A Common Stock of CYNOSURE, INC. |
|
| February 17, 2017 |
SC14D9C 1 d300812dsc14d9c.htm SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) CYNOSURE, INC. (Name of Subject Company) CYNOSURE, INC. (Name of Person Filing Statement) Class A Common Stock, $0.001 par value per share (Tit |
|
| February 17, 2017 |
EX-99.1 Exhibit 99.1 February 17, 2017 Dear SculpSure Customer, Earlier this week Hologic announced plans to the acquire Cynosure for $1.65 billion, which is expected to close in late March or early April 2017. Hologic is a global health care leader, and this strategic acquisition positions Cynosure to accelerate growth for its non-invasive body contouring offering. Assuming this transaction close |
|
| February 15, 2017 |
SC14D9C 1 d343362dsc14d9c.htm SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) CYNOSURE, INC. (Name of Subject Company) CYNOSURE, INC. (Name of Person Filing Statement) Class A Common Stock, $0.001 par value per share (Tit |
|
| February 15, 2017 |
EX-99.1 Exhibit 99.1 Cynosure to be Acquired by Hologic Dear Cynosure Supplier, We are writing to share some exciting news. Yesterday Cynosure announced that the company has entered into a definitive agreement to be acquired by Hologic, Inc., a global leader in diagnostics, breast imaging and surgical products with a focus on women?s health. Hologic is committed to the aesthetic business and to he |
|
| February 15, 2017 |
EX-99.2 Exhibit 99.2 February 15, 2017 Dear Cynosure MLT Customer, Yesterday Hologic announced plans to acquire Cynosure for $1.65 billion. Hologic is a 30 year-old company based in Marlborough, MA and is an established global leader in women?s health with strong relationships with OBGYNs and many other physician specialties. This strategic acquisition is part of Hologic?s commitment to global gro |
|
| February 14, 2017 |
EX-99.2 Exhibit 99.2 SUBJECT LINE: Cynosure to be Acquired by Hologic To our loyal and valued customer, I?m writing to share some exciting news. This morning Cynosure announced a definitive agreement to be acquired by Hologic, Inc., a global leader in diagnostics, breast imaging and surgical products with a focus on women?s health. This transaction, which is expected to close in late March or Apri |
|
| February 14, 2017 |
SUBJECT LINE: Cynosure Agrees to be Acquired by Hologic EX-99.1 Exhibit 99.1 SUBJECT LINE: Cynosure Agrees to be Acquired by Hologic Cynosure team, As you probably have read in this morning?s news release, today is a milestone day for our company. We have announced a definitive agreement to be acquired by Hologic, Inc. (Nasdaq: HOLX), a global leader in women?s health, which in 2016 generated revenues of more than $2.8 billion. We are excited by this o |
|
| February 14, 2017 |
SC14D9C 1 d343362dsc14d9c.htm SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) CYNOSURE, INC. (Name of Subject Company) CYNOSURE, INC. (Name of Person Filing Statement) Class A Common Stock, $0.001 par value per share (Tit |
|
| February 14, 2017 |
EX-2.1 EXHIBIT 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among CYNOSURE, INC., MINUTEMAN MERGER SUB, INC. and HOLOGIC, INC. Dated as of February 14, 2017 TABLE OF CONTENTS Page ARTICLE I The Cash Tender Offer 2 1.1 The Offer 2 1.2 Company Actions 5 ARTICLE II The Merger 7 2.1 The Merger; No Vote of Stockholders 7 2.2 Effective Time of the Merger 7 2.3 Closing 7 2.4 Effects of the M |
|
| February 14, 2017 |
EX-99.1 Exhibit 99.1 Hologic to Acquire Cynosure, Leader in Medical Aesthetics Systems and Technologies, in All-Cash Tender Offer that Combines Two Complementary Businesses - Expands Hologic?s Scientific and Commercial Expertise into Large, Adjacent Medical Device Segment Growing at Double-Digit Rate - - Accelerates Hologic?s Top- and Bottom-Line Growth Rates and is Immediately Accretive to Non-GA |
|
| February 14, 2017 |
8-K 1 d276853d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2017 CYNOSURE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporatio |
|
| February 14, 2017 |
Amendment to Amended and Restated By-laws Cynosure, Inc. EX-3.1 Exhibit 3.1 Amendment to Amended and Restated By-laws of Cynosure, Inc. The Amended and Restated By-laws of Cynosure, Inc. be and hereby are amended by adding thereto the following provision as a new Section 5.10 thereof: ?Section 5.10. Forum Selection By-law. Unless the corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware |
|
| February 14, 2017 |
SC14D9C 1 d327524dsc14d9c.htm SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) CYNOSURE, INC. (Name of Subject Company) CYNOSURE, INC. (Name of Person Filing Statement) Class A Common Stock, $0.001 par value per share (Tit |
|
| February 14, 2017 |
SC TO-C 1 a17-443618k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2017 HOLOGIC, INC. (Exact name of registrant as specified in its charter) Delaware 1-36214 04-2902449 (State or other jurisdiction of incorp |
|
| February 14, 2017 |
1 Acquisition of Cynosure February 14, 2017 Exhibit 99.2 1 Acquisition of Cynosure February 14, 2017 2 This news release contains forward-looking information that involves risks and uncertainties, including statements about each company?s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or otherwise incorporating judgments or estimates relating to future p |
|
| February 14, 2017 |
Exhibit 99.1 Hologic to Acquire Cynosure, Leader in Medical Aesthetics Systems and Technologies, in All-Cash Tender Offer that Combines Two Complementary Businesses ?Expands Hologic?s Scientific and Commercial Expertise into Large, Adjacent Medical Device Segment Growing at Double-Digit Rate ? ?Accelerates Hologic?s Top- and Bottom-Line Growth Rates and is Immediately Accretive to Non-GAAP Earning |
|
| February 14, 2017 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among CYNOSURE, INC., MINUTEMAN MERGER SUB, INC. and HOLOGIC, INC. Dated as of February 14, 2017 TABLE OF CONTENTS Page ARTICLE I The Cash Tender Offer 2 1.1 The Offer 2 1.2 Company Actions 5 ARTICLE II The Merger 7 2.1 The Merger; No Vote of Stockholders 7 2.2 Effective Time of the Merger 7 2.3 Closing 7 2.4 Effects of the Merger 7 |
|
| February 14, 2017 |
Exhibit 99.3 Edited Transcript for Investor Call Hologic, Inc. to Acquire Cynosure, Inc. February 14, 2017, 8:30AM EST CORPORATE PARTICIPANTS Mike Watts Hologic, Inc. - VP, IR & Corporate Communications Steve MacMillan Hologic, Inc. - Chairman, President & CEO Robert McMahon Hologic, Inc. - CFO CONFERENCE CALL PARTICIPANTS Mitchell Petersen Barclays Capital - Analyst Jon Block Stifel Nicolaus - An |
|
| February 14, 2017 |
CYNO / Cynosure, Inc. / Broadwood Partners LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2017 |
CYNO / Cynosure, Inc. / Point72 Asset Management, L.P. - SCHEDULE 13G/A, #1 Passive Investment SC 13G/A 1 p19726866a.htm SCHEDULE 13G/A, #1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CYNOSURE, INC. (Name of Issuer) Class A Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 232577205 (CUSIP Number) December 31, 2016 (Date of Event which Requires Filing of this Statement |
|
| February 14, 2017 |
EX-99.1 2 p19726866b.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behal |
|
| February 9, 2017 |
CYNO / Cynosure, Inc. / VANGUARD GROUP INC Passive Investment cynosureinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: Cynosure Inc Title of Class of Securities: Common Stock CUSIP Number: 232577205 Date of Event Which Requires Filing of this Statement: December 31, 2016 Check the appropriate box to designat |
|
| February 9, 2017 |
CYNO / Cynosure, Inc. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CYNOSURE INC-A (Name of Issuer) Common Stock (Title of Class of Securities) 232577205 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 7, 2017 |
EX-99.1 Exhibit 99.1 Cynosure Achieves Record Quarterly Revenue of $122.1 Million in the Fourth Quarter of 2016, Up 19 Percent Year-over-Year Fourth-Quarter 2016 Highlights: ? North American product revenue up 24 percent to $69.5 million ? International product revenue up 12 percent to $33.2 million ? GAAP earnings of $0.09 per diluted share includes $7.2 million charge related to previously discl |
|
| February 7, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d219871d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2017 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation |
|
| January 27, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2017 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation (Commission File Number) |
|
| December 16, 2016 |
8-K 1 d276941d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 14, 2016 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Juris- diction of Incor |
|
| November 14, 2016 |
CYNO / Cynosure, Inc. / Broadwood Partners LP Passive Investment SC 13G 1 d732118313-g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cynosure, Inc. (Name of Issuer) Class A Common Stock, $0.001 par value per share (Title of Class of Securities) 232577205 (CUSIP Number) November 1, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| November 7, 2016 |
Cynosure 10-Q (Quarterly Report) 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 25, 2016 |
EX-99.1 Exhibit 99.1 Contact: Timothy Baker Scott Solomon Chief Financial Officer Senior Vice President Cynosure, Inc. Sharon Merrill Associates (978) 256-4200 (617) 542-5300 [email protected] [email protected] Cynosure Announces Record Third-Quarter Revenues; Revenues Increase 36 Percent from Prior Year to $106.4 Million Third-Quarter 2016 Highlights: ? North American product revenue u |
|
| October 25, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d443333d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2016 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Juris- diction of Incorp |
|
| October 21, 2016 |
8-K 1 d272833d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2016 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Juris- diction of Incorp |
|
| October 12, 2016 |
LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Michael R. |
|
| September 13, 2016 |
Cynosure FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2016 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation (Commission F |
|
| September 13, 2016 |
EX-99.1 2 d255749dex991.htm EX-99.1 Exhibit 99.1 5 Carlisle Road Westford, MA 01886 www.cynosure.com t 978 256 4200 t 800 886 2966 f 978 256 6556 September 1, 2016 Stephen Webber Dear Steve: Cynosure, Inc. (“Cynosure,” “we,” “us” or “our”) is pleased to offer you the position of Executive Vice President, reporting directly to the Chief Executive Officer and exercising such powers, duties and respo |
|
| September 13, 2016 |
CYNOSURE, INC. CONSULTING AGREEMENT EX-99.2 3 d255749dex992.htm EX-99.2 Exhibit 99.2 CYNOSURE, INC. CONSULTING AGREEMENT This Consulting Agreement (this or the “Agreement”), dated as of September 12, 2016 is made between Cynosure, Inc., a Delaware corporation, having a principal place of business located at 5 Carlisle Road, Westford, Massachusetts 01886 (“Cynosure”), and Timothy W. Baker, an individual, having a principal place of b |
|
| August 5, 2016 |
Restated and Amended External Manufacturing Agreement EX-10.4 4 d193377dex104.htm EX-10.4 Exhibit 10.4 Restated and Amended External Manufacturing Agreement Whereas, Columbia Electrical Contractors, Inc. d/b/a Columbia Tech (“Columbia Tech”), a Massachusetts corporation with a principal place of business of 27 Otis Street, Westborough, MA 01581, through itself and its Affiliates, as hereinafter defined, provides contract manufacturing services; Where |
|
| August 5, 2016 |
Curo Westford, LLC c/o Curo Enterprises, LLC 20 West 22nd Street, Suite 408 New York, NY 10010 EX-10.2 2 d193377dex102.htm EX-10.2 Exhibit 10.2 Curo Westford, LLC c/o Curo Enterprises, LLC 20 West 22nd Street, Suite 408 New York, NY 10010 June 30, 2016 By Email Cynosure, Inc. 5 Carlisle Road Westford, MA 01886 Attention: Timothy Baker Email: [email protected] Re: Extension of Dates in Seventh Amendment of Lease Dear Timothy: Reference is hereby made to that certain Lease dated January 31, |
|
| August 5, 2016 |
EX-10.3 Exhibit 10.3 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. Execution Version EXCLUSIVE DISTRIBUTION AGREEMENT (for the Smartxide Quadro C60 surgical laser with DOT scanner Laser System) THIS AGREEMENT is made by and between El. En. S.p.A., a company organized under the laws of Italy whose address is Via B |
|
| August 5, 2016 |
Cynosure FORM 10-Q (Quarterly Report) Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 28, 2016 |
CORRESP July 28, 2016 By EDGAR Submission U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Martin James Kristin Lochhead Kate Tillan Laurie Abbott Geoff Kruczek Re: Cynosure, Inc. Form 10-K for the Fiscal Year Ended December 31, 2015 Filed February 29, 2016 Form 8-K filed April 26, 2016 File No. 000-51623 Ladies and Gentlemen: |
|
| July 26, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d226440d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2016 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporati |
|
| July 26, 2016 |
EX-99.1 Exhibit 99.1 Contact: Timothy Baker Scott Solomon Chief Financial Officer Senior Vice President Cynosure, Inc. Sharon Merrill Associates (978) 256-4200 (617) 542-5300 [email protected] [email protected] Cynosure Reports Net Income of $6.3 Million on Record Sales of $110.3 Million for the Second Quarter of 2016 Second-Quarter 2016 Highlights: ? North American product revenue up 4 |
|
| July 22, 2016 |
Cynosure FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2016 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation (Commission File N |
|
| May 26, 2016 |
SD 1 d175222dsd.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation (Commission File Number) (IRS Employer Identification No.) 5 Carlisle Road, Westford, MA 01886 (Address of Principal Executiv |
|
| May 26, 2016 |
EX-1.01 2 d175222dex101.htm EX-1.01 Exhibit 1.01 CYNOSURE, INC. Conflict Minerals Report For the reporting period from January 1, 2015 to December 31, 2015 This Conflict Minerals Report (the “Report”) of Cynosure, Inc. (“Cynosure,” the “Company,” “we,” “us” or “our”) has been prepared pursuant to Rule 13p-1 and Form SD (the “Rule”) promulgated under the Securities Exchange Act of 1934 for the repo |
|
| May 25, 2016 |
EX-99.1 Exhibit 99.1 Contact Scott Solomon Senior Vice President Sharon Merrill Associates 617-542-5300 [email protected] Cynosure Announces Planned Retirement of Timothy W. Baker as President, Chief Financial Officer and Chief Operating Officer Westford, Mass., May 25, 2016 ? Cynosure, Inc. (NASDAQ: CYNO) today announced that Timothy W. Baker has notified the Company that he plans to ret |
|
| May 25, 2016 |
8-K 1 d199541d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 24, 2016 CYNOSURE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Juris- diction of Incorporation ( |
|
| May 16, 2016 |
EX-3.2 3 d192056dex32.htm EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF CYNOSURE, INC. (Effective as of May 11, 2016) TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 1 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 3 1.10 Nomination of Directors 3 1.11 N |
|
| May 16, 2016 |
EX-3.1 2 d192056dex31.htm EX-3.1 Exhibit 3.1 SECOND RESTATED CERTIFICATE OF INCORPORATION OF CYNOSURE, INC. (originally incorporated on July 10, 1991 under the name Cynosure, Inc.) FIRST: The name of the Corporation is Cynosure, Inc. SECOND: The address of the Corporation’s registered office in the State of Delaware is Corporation Trust Center, 1209 North Orange Street, in the City of Wilmington, |
|
| May 16, 2016 |
8-K 1 d192056d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2016 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation) (C |
|
| May 10, 2016 |
EX-10.4 Exhibit 10.4 SEVENTH AMENDMENT OF LEASE THIS SEVENTH AMENDMENT OF LEASE (this ?Amendment?) is dated as of the 29th day of April, 2016, by and between CURO WESTFORD, LLC, a Massachusetts limited liability company (?Landlord?) and CYNOSURE, INC., a Delaware corporation (??Tenant??). BACKGROUND: A. Reference is made to the Lease between Glenborough Fund V, Limited Partnership, a Delaware limi |
|
| May 10, 2016 |
Cynosure 10-Q (Quarterly Report) 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 26, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d185065d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2016 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation) |
|
| April 26, 2016 |
EX-99.1 2 d185065dex991.htm EX-99.1 Exhibit 99.1 Contact: Timothy Baker Scott Solomon President, Chief Operating Officer Senior Vice President and Chief Financial Officer Sharon Merrill Associates Cynosure, Inc. (617) 542-5300 (978) 256-4200 [email protected] [email protected] Cynosure Announces Record First-Quarter 2016 Results; Revenues Increase 26% from Prior Year to $94.7 Million Fi |
|
| April 26, 2016 |
EX-99.1 2 c042616b.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf |
|
| April 26, 2016 |
CYNO / Cynosure, Inc. / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CYNOSURE, INC. (Name of Issuer) Class A Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 232577205 (CUSIP Number) April 25, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| April 1, 2016 |
DEFA14A 1 d121049ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ |
|
| April 1, 2016 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 14, 2016 |
PRE 14A 1 d121049dpre14a.htm PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the a |
|
| February 29, 2016 |
Cynosure FORM 10-K (Annual Report) Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 29, 2016 |
SUBSIDIARIES OF THE REGISTRANT EX-21.1 2 d107402dex211.htm EX-21.1 SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 SUBSIDIARY JURISDICTION OF INCORPORATION S.A.R.L. Cynosure France France Cynosure Maroc SARL France Cynosure Langen GmbH Germany Cynosure K.K. Japan Cynosure UK LTD United Kingdom Cynosure Spain S.L. Spain Cynosure Securities Corporation United States Suzhou Cynosure Medical Devices Company Ltd. China Cynosure Mexico, |
|
| February 10, 2016 |
Cynosure SC 13G AMENDMENT NO. 1 (Passive Acquisition of More Than 5% of Shares) SC 13G Amendment No. 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)1 Cynosure, Inc. (Name of Issuer) Common Stock, Class A, $.001 par value (Title of Class of Securities) 232577205 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 9, 2016 |
EX-99.1 Exhibit 99.1 Contact: Timothy Baker Scott Solomon President, Chief Operating Officer Senior Vice President and Chief Financial Officer Sharon Merrill Associates Cynosure, Inc. (617) 542-5300 (978) 256-4200 [email protected] [email protected] Cynosure Announces Fourth-Quarter 2015 Results; Achieves Record Quarterly Revenue of $102.4 Million, 19 Percent Increase from Prior Year Fo |
|
| February 9, 2016 |
Cynosure FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2016 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 5, 2016 |
8-K 1 d107301d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2016 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorpor |
|
| February 5, 2016 |
Cynosure, Inc. NON-EQUITY INCENTIVE PLAN EX-10.1 3 d107301dex101.htm EX-10.1 Exhibit 10.1 Cynosure, Inc. NON-EQUITY INCENTIVE PLAN 1. PURPOSES OF THE PLAN The purposes of the Plan are to advance the interests of the Company and its stockholders and to motivate and retain executive officers of the Company and its Affiliates to achieve targeted levels of corporate, financial and strategic performance. 2. DEFINITIONS 2.1. “Affiliate” shall |
|
| February 5, 2016 |
EX-10.2 4 d107301dex102.htm EX-10.2 Exhibit 10.2 CYNOSURE, INC. Performance-Based Stock Unit Agreement Granted Under the Amended and Restated 2005 Stock Incentive Plan 1. Grant of Award. This Agreement evidences the grant by Cynosure, Inc., a Delaware corporation (the “Company”) on , 201 (the “Grant Date”) to you (the “Participant”) of performance-based stock units of the Company (individually, a |
|
| February 5, 2016 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF CYNOSURE, INC. (Effective as of February 3, 2016) TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 1 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 3 1.10 Nomination of Directors 3 1.11 Notice of Business at A |
|
| November 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 27, 2015 |
EX-99.1 2 d19471dex991.htm EX-99.1 Exhibit 99.1 Contact: Timothy Baker Scott Solomon President, Chief Operating Officer Senior Vice President and Chief Financial Officer Sharon Merrill Associates Cynosure, Inc. (617) 542-5300 (978) 256-4200 [email protected] [email protected] Cynosure Announces Third-Quarter 2015 Results; Revenue of $78.4 Million, 10 Percent Increase from Prior Year Thi |
|
| October 27, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d19471d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2015 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorpora |
|
| August 5, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000 |
|
| July 28, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d41663d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2015 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporatio |
|
| July 28, 2015 |
EX-99.1 Exhibit 99.1 Contact: Timothy Baker Scott Solomon President, Chief Operating Officer Vice President and Chief Financial Officer Sharon Merrill Associates Cynosure, Inc. (617) 542-5300 (978) 256-4200 [email protected] [email protected] Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year Second-Quarter Highlights: ? North |
|
| July 22, 2015 |
CORRESP 5 Carlisle Road Westford, MA 01886 www.cynosure.com t 978 256 4200 t 800 886 2966 f 978 256 6556 July 22, 2015 By EDGAR Submission U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Cecilia Blye Re: Cynosure, Inc. Form 10-K for Fiscal Year Ended December 31, 2014 Filed March 13, 2015 File No. 0-51623 Ladies and Gentlemen |
|
| May 28, 2015 |
EX-1.01 2 d929898dex101.htm EX-1.01 Exhibit 1.01 CYNOSURE, INC. Conflict Minerals Report For the reporting period from January 1, 2014 to December 31, 2014 This Conflict Minerals Report (the “Report”) of Cynosure, Inc. has been prepared pursuant to Rule 13p-1 and Form SD (the “Rule”) promulgated under the Securities Exchange Act of 1934 for the reporting period January 1, 2014 to December 31, 2014 |
|
| May 28, 2015 |
SD 1 d929898dsd.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation (Commission File Number) (IRS Employer Identification No.) 5 Carlisle Road, Westford, MA 01886 (Address of Principal Executiv |
|
| May 18, 2015 |
Submission of Matters to a Vote of Security Holders 8-K 1 d928104d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2015 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporatio |
|
| May 7, 2015 |
EX-10.1 2 d908333dex101.htm EX-10.1 Exhibit 10.1 SIXTH AMENDMENT THIS SIXTH AMENDMENT (the “Sixth Amendment”) is made and entered into as of the 16th day of April, 2015 (the “Execution Date”), by and between GLENBOROUGH WESTFORD CENTER, LLC, a Delaware limited liability company (“Landlord”), and CYNOSURE, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are parties to that |
|
| May 7, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 d908333d10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from |
|
| May 5, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d920143d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2015 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation (Com |
|
| May 5, 2015 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Timothy Baker Scott Solomon President, Chief Operating Officer and Chief Financial Officer Vice President Cynosure, Inc. Sharon Merrill Associates (978) 256-4200 (617) 542-5300 [email protected] [email protected] Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior |
|
| May 4, 2015 |
DEFA14A 1 d920187ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ |
|
| April 3, 2015 |
DEFA14A 1 d864027ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ |
|
| April 3, 2015 |
DEF 14A 1 d864027ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the a |
|
| March 13, 2015 |
EX-10.16 Exhibit 10.16 FOURTH AMENDMENT THIS FOURTH AMENDMENT (this “Fourth Amendment”) is made and entered into as of December 20, 2012, by and between GLENBOROUGH WESTFORD CENTER, LLC, a Delaware limited liability company (“Landlord”), and CYNOSURE, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord (as successor in interest to Glenborough Fund V, Limited Partnership) and Tenant are p |
|
| March 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 13, 2015 |
EX-10.21 Exhibit 10.21 Cynosure, Inc. Memorandum TO: <> (the “Grantee”) FROM: Timothy W. Baker, President & Chief Financial Officer SUBJECT: Restricted Stock Unit Agreement DATE: February 11, 2015 You have been granted, under the Cynosure, Inc. Amended and Restated 2005 Stock Incentive Plan (the “Plan”), an award of Restricted Stock Units (“RSUs”) (the RSUs are collectively referred to as the “Awa |
|
| March 13, 2015 |
SECOND AMENDMENT TO EMPLOYMENT AGREEMENT EX-10.10 Exhibit 10.10 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT THIS SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is entered into as of July 20, 2011 by and between Cynosure, Inc., a Delaware corporation (the “Company”) and Michael R. Davin (the “Executive”). WHEREAS, the Company and the Executive are parties to that certain Employment Agreement dated as of December 1, 2008, as amen |
|
| March 13, 2015 |
SUBSIDIARIES OF THE REGISTRANT EX-21.1 SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 SUBSIDIARY JURISDICTION OF INCORPORATION S.A.R.L. Cynosure France France Cynosure Maroc SARL France Cynosure Langen GmbH Germany Cynosure K.K. Japan Cynosure UK LTD United Kingdom Cynosure Spain S.L. Spain Cynosure Securities Corporation United States Suzhou Cynosure Medical Devices Company Ltd. China Cynosure Mexico Mexico Cynosure Korea Limited |
|
| February 11, 2015 |
CYNO / Cynosure, Inc. / TimesSquare Capital Management, LLC - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )1 Cynosure, Inc. (Name of Issuer) Common Stock, Class A, $.001 par value (Title of Class of Securities) 232577205 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 10, 2015 |
Cynosure Reports Record Quarterly Revenue of $86.3 Million for the Fourth Quarter of 2014 EX-99.1 Exhibit 99.1 Contact: Timothy Baker Scott Solomon President and Chief Financial Officer Vice President Cynosure, Inc. Sharon Merrill Associates (978) 256-4200 (617) 542-5300 [email protected] [email protected] Cynosure Reports Record Quarterly Revenue of $86.3 Million for the Fourth Quarter of 2014 Westford, MA – February 10, 2015 – Cynosure, Inc. (Nasdaq: CYNO), which designs, |
|
| February 10, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2015 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 7, 2014 |
EX-99.3 5 d816120dex993.htm EX-99.3 Exhibit 99.3 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION On September 5, 2014, Cynosure, Inc. (“Cynosure”) acquired substantially all of the assets of Ellman International, Inc. (“Ellman”) for a cash purchase price of approximately $13.2 million. In addition, Cynosure assumed certain contractual and current liabilities. The purchase price was based primar |
|
| November 7, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 7, 2014 |
Financial Statements and Exhibits Form 8-K Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2014 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdicti |
|
| November 7, 2014 |
EX-99.1 Exhibit 99.1 INDEPENDENT AUDITORS’ REPORT To the Board of Directors and Stockholders of Cynosure, Inc.; and To the Former Stockholders and Board of Directors of Ellman Holding Corporation and Subsidiaries Report on the Consolidated Financial Statements We have audited the accompanying consolidated financial statements of Ellman Holding Corporation and Subsidiaries, which comprise the conso |
|
| November 7, 2014 |
EX-99.2 4 d816120dex992.htm EX-99.2 Exhibit 99.2 ELLMAN HOLDING CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS As of June 30, 2014 and December 31, 2013 (amounts in thousands) Unaudited 2014 Audited 2013 ASSETS CURRENT ASSETS Cash and cash equivalents $ 1,342 $ 570 Accounts receivable, less allowance for doubtful accounts of $408 at June 30, 2014 and December 31, 2013 3,483 4,193 Invento |
|
| October 28, 2014 |
Cynosure Reports Record Third-Quarter Revenue of $71.5 Million, Up 18% Year-Over-Year EX-99.1 Exhibit 99.1 Contact: Timothy Baker Scott Solomon President and Chief Financial Officer Vice President Cynosure, Inc. Sharon Merrill Associates (978) 256-4200 (617) 542-5300 [email protected] [email protected] Cynosure Reports Record Third-Quarter Revenue of $71.5 Million, Up 18% Year-Over-Year Westford, MA – October 28, 2014 – Cynosure, Inc. (Nasdaq: CYNO), which designs, manuf |
|
| October 28, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d808306d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2014 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorpor |
|
| October 6, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2014 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation (Commission F |
|
| September 8, 2014 |
EX-99.1 Exhibit 99.1 Contact: Scott Solomon Vice President Sharon Merrill Associates, Inc. Phone: (617) 542-5300 [email protected] Cynosure Acquires Assets of RF Medical Device Manufacturer Ellman International, Inc. Deal Complements Cynosure’s Platform with Radiofrequency Energy Sources and Accessory Products for Aesthetic and Surgical Indications; Management to Discuss Transaction in Co |
|
| September 8, 2014 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events 8-K 1 d785290d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 5, 2014 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction Of Incorpora |
|
| September 8, 2014 |
EX-2.1 Exhibit 2.1 EXECUTION VERSION ASSET PURCHASE AGREEMENT by and among CYNOSURE, INC., as Buyer, ELLMAN INTERNATIONAL, INC., as Seller, and ELLMAN HOLDINGS, INC. and ELLMAN HOLDING CORPORATION, as the Holding Companies Dated as of September 5, 2014 ARTICLE I SALE AND PURCHASE; ASSUMPTION; CLOSING 1 1.1 Sale and Purchase of Assets; Assumption of Assumed Liabilities 1 1.2 Pre-Closing 6 1.3 Locat |
|
| August 11, 2014 |
CYNO / Cynosure, Inc. / WELLS FARGO & COMPANY/MN Passive Investment SC 13G/A 1 wfcynosurein-232577205x.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) CYNOSURE INC (Name of Issuer) CL A (Title of Class of Securities) 232577205 (CUSIP Number) July 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| August 11, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000 |
|
| July 30, 2014 |
8-K 1 d767068d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2014 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation (C |
|
| July 29, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d765548d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2014 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporati |
|
| July 29, 2014 |
Cynosure Reports Second-Quarter 2014 Financial Results EX-99.1 Exhibit 99.1 Contact: Timothy Baker Scott Solomon Executive Vice President, Vice President Chief Operating Officer Sharon Merrill Associates and Chief Financial Officer (617) 542-5300 Cynosure, Inc. [email protected] (978) 256-4200 [email protected] Cynosure Reports Second-Quarter 2014 Financial Results Westford, MA – July 29, 2014 – Cynosure, Inc. (Nasdaq: CYNO), which develops |
|
| June 20, 2014 |
8-K 1 d741286d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2014 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporati |
|
| June 20, 2014 |
EX-99.1 2 d741286dex991.htm EX-99.1 Exhibit 99.1 NOTICE OF BLACKOUT PERIOD TO: Directors and Executive Officers of Cynosure, Inc. FROM: Timothy W. Baker, Executive Vice President, Chief Operating Officer and Chief Financial Officer Patricia A. Davis, Esq., General Counsel DATE: June 20, 2014 Please be advised that on June 20, 2014, Cynosure, Inc. (the “Company”) received notice of an upcoming susp |
|
| June 2, 2014 |
EX-1.02 Exhibit 1.02 CYNOSURE, INC. Conflict Minerals Report For the reporting period from January 1, 2013 to December 31, 2013 This Conflict Minerals Report (the “Report”) of Cynosure, Inc. has been prepared pursuant to Rule 13p-1 and Form SD (the “Rule”) promulgated under the Securities Exchange Act of 1934 for the reporting period January 1, 2013 to December 31, 2013. The Rule requires disclosu |
|
| June 2, 2014 |
FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation (Commission File Number) (IRS Employer Identification No.) 5 Carlisle Road, Westford, MA 01886 (Address of Principal Executive Offices) (Zip |
|
| May 15, 2014 |
Submission of Matters to a Vote of Security Holders - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2014 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation (Commission File Nu |
|
| May 9, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 d707793d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period |
|
| May 6, 2014 |
EX-99.1 Exhibit 99.1 Contact: Timothy Baker Scott Solomon Executive Vice President, Vice President Chief Operating Officer Sharon Merrill Associates and Chief Financial Officer (617) 542-5300 Cynosure, Inc. [email protected] (978) 256-4200 [email protected] Cynosure Reports First-Quarter 2014 Financial Results Board of Directors Increases Share Repurchase Program to $35 Million Westford |
|
| May 6, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d723165d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2014 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation |
|
| April 4, 2014 |
DEFA14A 1 d694698ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ |
|
| April 4, 2014 |
DEF 14A 1 d694698ddef14a.htm DEFINITIVE PROXY STATEMENT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Regis |
|
| March 17, 2014 |
SUBSIDIARIES OF THE REGISTRANT EX-21.1 3 d657890dex211.htm EX-21.1 SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 SUBSIDIARY JURISDICTION OF INCORPORATION Cynosure France France Cynosure GmbH Germany Cynosure K.K. Japan Cynosure UK Ltd. United Kingdom Cynosure Spain S.L. Spain Cynosure Securities Corporation United States Suzhou Cynosure Medical Devices Company Ltd. China Cynosure Mexico Mexico Cynosure Korea Limited Korea Cynosur |
|
| March 17, 2014 |
SEPARATION AGREEMENT AND RELEASE Exhibit 10.15 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (the ?Agreement?) is made as of this 6th day of September, 2013, by and between Cynosure, Inc. (?Cynosure?) and Palomar Medical Technologies, LLC (formerly Palomar Medical Technologies, Inc., ?Palomar?) (collectively, the ?Company?), on the one hand, and Joseph P. Caruso (?Mr. Caruso?), on the other hand (together |
|
| March 17, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 14, 2014 |
CYNO / Cynosure, Inc. / Archon Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d677464d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2014 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorpo |
|
| February 12, 2014 |
CYNO / Cynosure, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - CYNO AS OF 12/31/2013 Passive Investment SC 13G/A 1 cyno13gadec13.htm CYNO AS OF 12/31/2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CYNOSURE INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 232577205 (CUSIP Number) December 31, 2013 (Date of Event which Requires Filing of Statement) Check the appropriate box to design |
|
| February 12, 2014 |
Cynosure Reports Record Fourth Quarter Revenue of $74.5 million, up 75% Year-over-Year EX-99.1 Exhibit 99.1 Contacts: Timothy Baker Scott Solomon EVP, COO and CFO Vice President Cynosure, Inc. Sharon Merrill 978-256-4200 617-542-5300 [email protected] [email protected] Cynosure Reports Record Fourth Quarter Revenue of $74.5 million, up 75% Year-over-Year Financial Highlights • Non-GAAP net income of $8.7 million, or $0.39 per diluted share, for Q4 2013, excluding acquisit |
|
| January 27, 2014 |
CYNO / Cynosure, Inc. / WELLS FARGO & COMPANY/MN Passive Investment SC 13G 1 wfcynosurein-232577205.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) CYNOSURE INC (Name of Issuer) CL A (Title of Class of Securities) 232577205 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| December 2, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 d636009d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2013 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorpo |
|
| December 2, 2013 |
EX-99.1 Exhibit 99.1 Contact: Scott Solomon Vice President Sharon Merrill 617.542.5300 [email protected] Cynosure Announces Sale of Burlington, MA Office Building Former Headquarters of Palomar Medical Technologies Purchased for Approximately $25.8 Million Westford, Mass., December 2, 2013 – Cynosure, Inc. (NASDAQ: CYNO) today announced that it has sold the former Palomar Medical Technolo |
|
| December 2, 2013 |
EX-10.1 2 d636009dex101.htm EX-10.1 Exhibit 10.1 PURCHASE AND SALE AGREEMENT THIS PURCHASE AND SALE AGREEMENT (“Agreement”) is made as of this 25th day of November, 2013 (“Effective Date”) by and between PALOMAR MEDICAL TECHNOLOGIES, LLC, a Delaware limited liability company, having a mailing address of 5 Carlisle Road, Westford, MA 01886 (the “Seller”) and NETWORK DRIVE OWNER LLC, a Delaware limi |
|
| November 22, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 d633849d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2013 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorpo |
|
| November 22, 2013 |
EX-10.1 Exhibit 10.1 FIFTH AMENDMENT THIS FIFTH AMENDMENT (the “Fifth Amendment”) is made and entered into as of the 18th day of November, 2013 (“Execution Date”), by and between GLENBOROUGH WESTFORD CENTER, LLC, a Delaware limited liability company (“Landlord”), and CYNOSURE, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are parties to that certain lease dated January 3 |
|
| November 12, 2013 |
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.2 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this ?Amendment?) is by and between Cynosure, Inc., a Delaware corporation (the ?Company?), and Timothy W. Baker (the ?Executive?). WHEREAS, the Company and the Executive are parties to that certain Employment Agreement having an effective date of December 15, 2008 (the ?Agreement?), pursuant to whic |
|
| November 12, 2013 |
THIRD AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.1 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT THIS THIRD AMENDMENT TO EMPLOYMENT AGREEMENT (this ?Amendment?) is by and between Cynosure, Inc., a Delaware corporation (the ?Company?), and Michael R. Davin (the ?Executive?). WHEREAS, the Company and the Executive are parties to that certain Employment Agreement having an effective date of December 15, 2008, as amended on December 20, 2010 an |
|
| November 12, 2013 |
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.3 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this ?Amendment?) is by and between Cynosure, Inc., a Delaware corporation (the ?Company?), and Douglas J. Delaney (the ?Executive?). WHEREAS, the Company and the Executive are parties to that certain Employment Agreement having an effective date of December 15, 2008 (the ?Agreement?), pursuant to wh |
|
| November 12, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number |
|
| October 29, 2013 |
EX-99.1 2 d619163dex991.htm EX-99.1 Exhibit 99.1 Contacts: Timothy Baker Scott Solomon EVP, COO and CFO Vice President Cynosure, Inc. Sharon Merrill 978-256-4200 617-542-5300 [email protected] [email protected] Cynosure Reports Third-Quarter 2013 Financial Results Company Achieves Significant Progress in Integration of Palomar; Board Authorizes $25 Million Share Repurchase Program WESTF |
|
| October 29, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2013 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation (Commission File Number) |
|
| September 6, 2013 |
Financial Statements and Exhibits 8-K/A 1 d591206d8ka.htm AMENDMENT NO. 1 TO FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2013 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (St |
|
| September 6, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2013 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation (Commission File Number |
|
| September 6, 2013 |
EX-99.3 3 d591206dex993.htm EX-99.3 Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On June 24, 2013, Cynosure, Inc. (“Cynosure”) completed its acquisition of Palomar Medical Technologies, Inc., (“Palomar”), pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of May 15, 2013 (the “Merger Agreement”), by and among Cynosure, a Delaware c |
|
| August 9, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 d544688d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period f |
|
| August 9, 2013 |
EX-10.1 Exhibit 10.1 CYNOSURE, INC. AMENDED AND RESTATED 2005 STOCK INCENTIVE PLAN (as amended by the Board of Directors on April 12, 2013 and approved by the stockholders on June 24, 2013) 1. Purpose The purpose of this Amended and Restated 2005 Stock Incentive Plan (the “Plan”) of Cynosure, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by |
|
| July 31, 2013 |
Cynosure Reports Second-Quarter 2013 Financial Results EX-99.1 2 d575501dex991.htm EX-99.1 Exhibit 99.1 Contacts: Timothy Baker Scott Solomon EVP, COO and CFO Vice President Cynosure, Inc. Sharon Merrill 978-256-4200 617-542-5300 [email protected] [email protected] Cynosure Reports Second-Quarter 2013 Financial Results • Record Revenue of $50.1 Million, Up 27% From Q2 of 2012 • Adjusted EPS of $0.29, Excluding Acquisition Costs • GAAP Net L |
|
| July 31, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d575501d8k.htm FORN 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2013 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Juris- diction of Incorpora |
|
| July 3, 2013 |
Form S-8 As filed with the Securities and Exchange Commission on July 3, 2013 Registration No. |
|
| July 3, 2013 |
EX-99.1 4 d563250dex991.htm EX-99.1 Exhibit 99.1 CYNOSURE, INC. AMENDED AND RESTATED 2005 STOCK INCENTIVE PLAN (as amended by the Board of Directors on April 12, 2013 and approved by the stockholders on June 24, 2013) 1. Purpose The purpose of this Amended and Restated 2005 Stock Incentive Plan (the “Plan”) of Cynosure, Inc., a Delaware corporation (the “Company”), is to advance the interests of t |
|
| June 25, 2013 |
Cynosure Completes Acquisition of Palomar Medical Technologies EX-99.1 2 d558031dex991.htm EX-99.1 Exhibit 99.1 Contacts: Timothy Baker Scott Solomon Executive Vice President, Chief Operating Officer and Chief Financial Officer Vice President Sharon Merrill Cynosure, Inc. 617.542.5300 978.256.4200 [email protected] [email protected] Cynosure Completes Acquisition of Palomar Medical Technologies • Completion Follows Approvals by Cynosure Stockholder |
|
| June 25, 2013 |
SC 13D/A Amendment No.1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Cynosure, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 232577205 (CUSIP Number) Copies |
|
| June 25, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2013 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 14, 2013 |
425 1 d554559d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2013 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporati |
|
| June 14, 2013 |
8-K 1 d554559d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2013 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporati |
|
| June 10, 2013 |
425 1 d552028d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2013 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporatio |
|
| June 10, 2013 |
Palomar Signs Memorandum of Understanding Regarding Settlement of Delaware Merger Litigation EX-99.1 2 d552028dex991.htm EX-99.1 Exhibit 99.1 Contacts: Kerry McAnistan Investor Relations Assistant Palomar Medical Technologies, Inc. 781-993-2411 [email protected] Palomar Signs Memorandum of Understanding Regarding Settlement of Delaware Merger Litigation Burlington, MA– June 10, 2013 –Palomar Medical Technologies, Inc. (NASDAQ: PMTI) today announced that it has entered into a memorandu |
|
| June 10, 2013 |
Financial Statements and Exhibits, Other Events 8-K 1 d552028d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2013 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporatio |
|
| June 10, 2013 |
Palomar Signs Memorandum of Understanding Regarding Settlement of Delaware Merger Litigation EX-99.1 2 d552028dex991.htm EX-99.1 Exhibit 99.1 Contacts: Kerry McAnistan Investor Relations Assistant Palomar Medical Technologies, Inc. 781-993-2411 [email protected] Palomar Signs Memorandum of Understanding Regarding Settlement of Delaware Merger Litigation Burlington, MA– June 10, 2013 –Palomar Medical Technologies, Inc. (NASDAQ: PMTI) today announced that it has entered into a memorandu |
|
| May 23, 2013 |
Amendment No. 2 to Form S-4 Table of Contents As filed with the Securities and Exchange Commission on May 23, 2013 Registration No. 333-187895 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO Form S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYNOSURE, INC. (Exact name of registrant as specified in its charter) Delaware 3845 04-3125110 (State |
|
| May 23, 2013 |
PROPOSED MERGER—YOUR VOTE IS VERY IMPORTANT 424B3 1 d503926d424b3.htm 424(B)(3) Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-187895 PROPOSED MERGER—YOUR VOTE IS VERY IMPORTANT The board of directors of each of Cynosure, Inc. and Palomar Medical Technologies, Inc. has approved an agreement and plan of merger pursuant to which Cynosure will acquire Palomar through the merger of Palomar with and into a newly formed, |
|
| May 21, 2013 |
425 1 d503926d425.htm 425 Filed by Cynosure, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Palomar Medical Technologies, Inc. Commission File No.: 333-187895 Cynosure’s CEO Presents at UBS Global Healthcare Conference (Transcript) May 21 2013 Executives Michael Davin—Chairman, President |
|
| May 16, 2013 |
EX-99.5 Exhibit 99.5 SPECIAL MEETING OF STOCKHOLDERS OF PALOMAR MEDICAL TECHNOLOGIES, INC. June 24, 2013 PROXY VOTING INSTRUCTIONS INTERNET - Access “www.voteproxy.com” and follow the on-screen instructions. Have your proxy card available when you access the web page. TELEPHONE - Call toll-free 1-800-PROXIES (1-800-776-9437) in the United States or 1-718-921-8500 from foreign countries from any to |
|
| May 16, 2013 |
S-4/A 1 d503926ds4a.htm AMENDMENT NO. 1 TO S-4 Table of Contents As filed with the Securities and Exchange Commission on May 16, 2013 Registration No. 333-187895 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO Form S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYNOSURE, INC. (Exact name of registrant as specified in its charter) Delaware 384 |
|
| May 16, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 d540111d8k.htm FORM 8-K/425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2013 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorpor |
|
| May 16, 2013 |
EX-99.4 Exhibit 99.4 1 ¢ CYNOSURE, INC. CLASS A COMMON STOCK PROXY FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD JUNE 24, 2013 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS By signing on the reverse side, you acknowledge that you have received notice of the Annual Meeting of Stockholders and the board of directors’ proxy statement for the Annual Meeting, you revoke all prior prox |
|
| May 16, 2013 |
EX-2.1 2 d540111dex21.htm EX-2.1 Exhibit 2.1 AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER by and among CYNOSURE, INC., COMMANDER ACQUISITION, LLC and PALOMAR MEDICAL TECHNOLOGIES, INC. Dated as of May 15, 2013 TABLE OF CONTENTS ARTICLE I THE MERGER 2 1.1 Effective Time of the Merger. 2 1.2 Closing. 2 1.3 Effects of the Merger. 3 1.4 Managers and Officers of the Surviving Entity. 3 ARTICLE II |
|
| May 16, 2013 |
EX-2.1 2 d540111dex21.htm EX-2.1 Exhibit 2.1 AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER by and among CYNOSURE, INC., COMMANDER ACQUISITION, LLC and PALOMAR MEDICAL TECHNOLOGIES, INC. Dated as of May 15, 2013 TABLE OF CONTENTS ARTICLE I THE MERGER 2 1.1 Effective Time of the Merger. 2 1.2 Closing. 2 1.3 Effects of the Merger. 3 1.4 Managers and Officers of the Surviving Entity. 3 ARTICLE II |
|
| May 16, 2013 |
Merger Prospectus - FORM 8-K/425 425 1 d540111d8k.htm FORM 8-K/425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2013 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorpor |
|
| May 8, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 d502783d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period |
|
| April 30, 2013 |
Cynosure Reports First-Quarter 2013 Financial Results EX-99.1 Exhibit 99.1 Timothy Baker Scott Solomon Executive VP, Treasurer and CFO Vice President Cynosure, Inc. Sharon Merrill 978.256.4200 617.542.5300 [email protected] [email protected] Cynosure Reports First-Quarter 2013 Financial Results • Revenue of $40.7 Million, Up 19% From Q1 2012; • Adjusted EPS of $0.12 Excluding Acquisition-Related Costs; • GAAP EPS of $0.07 Including Acquisi |
|
| April 30, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2013 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation (Commission File Number) ( |
|
| April 30, 2013 |
425 1 d527472d425.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2013 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation |
|
| April 29, 2013 |
10-K/A 1 d527436d10ka.htm FORM 10-K AMENDMENT NO. 1 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT |
|
| April 24, 2013 |
Financial Statements and Exhibits, Other Events 8-K 1 d526631d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2013 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporat |
|
| April 24, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2013 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 24, 2013 |
Cynosure and Palomar Announce Date for Stockholder Meetings EX-99.1 Exhibit 99.1 Contacts: Scott Solomon Kerry McAnistan Vice President Investor Relations Assistant Sharon Merrill Associates, Inc. Palomar Medical Technologies, Inc. 617.542.5300 781-993-2411 [email protected] [email protected] Cynosure and Palomar Announce Date for Stockholder Meetings Westford, MA and Burlington, MA– April 24, 2013 – Cynosure, Inc. (NASDAQ: CYNO) and Palomar M |
|
| April 24, 2013 |
Cynosure and Palomar Announce Date for Stockholder Meetings EX-99.1 2 d526631dex991.htm EX-99.1 Exhibit 99.1 Contacts: Scott Solomon Kerry McAnistan Vice President Investor Relations Assistant Sharon Merrill Associates, Inc. Palomar Medical Technologies, Inc. 617.542.5300 781-993-2411 [email protected] [email protected] Cynosure and Palomar Announce Date for Stockholder Meetings Westford, MA and Burlington, MA– April 24, 2013 – Cynosure, Inc. |
|
| April 12, 2013 |
S-4 1 d503926ds4.htm S-4 Table of Contents As filed with the Securities and Exchange Commission on April 12, 2013 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYNOSURE, INC. (Exact name of registrant as specified in its charter) Delaware 3845 04-3125110 (State or other jurisdiction of |
|
| April 12, 2013 |
EX-99.8 4 d503926dex998.htm EX-99.8 Exhibit 99.8 CONSENT OF LEERINK SWANN LLC We hereby consent to (i) the use of our opinion letter dated March 17, 2013 to the Board of Directors of Cynosure, Inc. (“Cynosure”) included in Annex D to the Joint Proxy Statement/Prospectus relating to the proposed merger of Palomar Medical Technologies, Inc. with and into Commander Acquisition Corp., a wholly-owned s |
|
| April 12, 2013 |
EX-99.9 5 d503926dex999.htm EX-99.9 Exhibit 99.9 April 12, 2013 Board of Directors Palomar Medical Technologies, Inc. 15 Network Drive Burlington, MA 01803 The Board of Directors of Palomar Medical Technologies, Inc.: We hereby consent to the inclusion of our opinion letter, dated March 17, 2013, to the Board of Directors of Palomar Medical Technologies, Inc. (“Palomar”) as Annex E to, and to the |
|
| March 21, 2013 |
CYNO / Cynosure, Inc. / PALOMAR MEDICAL TECHNOLOGIES INC - SCHEDULE 13D Activist Investment Schedule 13D SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| March 21, 2013 |
PMTI / Palomar Medical Technologies Llc / CYNOSURE INC - SCHEDULE 13D Activist Investment Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Palomar Medical Technologies, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 697529303 (CUSIP Number) Benjamin A. Kaplan, Esquire Senior Vice President and General Counsel Cynosure, Inc. 5 Carlisl |
|
| March 18, 2013 |
Cynosure Signs Definitive Agreement to Acquire Palomar Medical Technologies EX-99.2 Exhibit 99.2 Cynosure Signs Definitive Agreement to Acquire Palomar Medical Technologies March 18, 2013 Forward-Looking Statements With the exception of the historical information contained in this presentation, the matters described herein contain forward-looking statements, including, but not limited to, statements relating to long-term growth and profitability, projected synergies, the |
|
| March 18, 2013 |
EX-99.1 4 d503688dex991.htm EX-99.1 Exhibit 99.1 Contacts: Scott Solomon Kerry McAnistan Vice President Investor Relations Assistant Sharon Merrill Associates, Inc. Palomar Medical Technologies, Inc. 617.542.5300 781-993-2411 [email protected] [email protected] Cynosure Signs Definitive Agreement to Acquire Palomar Medical Technologies • Creates One of World’s Premier Aesthetic Laser |
|
| March 18, 2013 |
THIRD AMENDMENT TO EMPLOYMENT AGREEMENT EX-10.3 Exhibit 10.3 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This shall serve as the Third Amendment to the Employment Agreement (this “Amendment”) entered into as of this 17 day of March, 2013, between Palomar Medical Technologies, Inc., a Delaware corporation (the “Company”), and Joseph P. Caruso, an individual (the “Executive”). WHEREAS, the Company and the Executive are parties to a certain Em |
|
| March 18, 2013 |
EX-99.1 8 d503633dex991.htm EX-99.1 Exhibit 99.1 Contacts: Scott Solomon Kerry McAnistan Vice President Investor Relations Assistant Sharon Merrill Associates, Inc. Palomar Medical Technologies, Inc. 617.542.5300 781-993-2411 [email protected] [email protected] Cynosure Signs Definitive Agreement to Acquire Palomar Medical Technologies • Creates One of World’s Premier Aesthetic Laser |
|
| March 18, 2013 |
Cynosure Signs Definitive Agreement to Acquire Palomar Medical Technologies EX-99.2 5 d503688dex992.htm EX-99.2 Exhibit 99.2 Cynosure Signs Definitive Agreement to Acquire Palomar Medical Technologies March 18, 2013 Forward-Looking Statements With the exception of the historical information contained in this presentation, the matters described herein contain forward-looking statements, including, but not limited to, statements relating to long-term growth and profitabilit |
|
| March 18, 2013 |
EX-10.1 Exhibit 10.1 COMPANY STOCKHOLDER AGREEMENT This Stockholder Agreement (this “Agreement”), dated as of March 17, 2013, is entered into by and between Cynosure, Inc., a Delaware corporation (the “Buyer”), and the undersigned stockholder (“Stockholder”) of Palomar Medical Technologies, Inc., a Delaware corporation (the “Company”). WHEREAS, concurrently with the execution of this Agreement, th |
|
| March 18, 2013 |
EX-2.1 2 d503633dex21.htm EX-2.1 Table of Contents Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among CYNOSURE, INC., COMMANDER ACQUISITION CORP. and PALOMAR MEDICAL TECHNOLOGIES, INC. Dated as of March 17, 2013 Table of Contents TABLE OF CONTENTS ARTICLE I THE MERGER 1 1.1 Effective Time of the Merger 1 1.2 Closing 1 1.3 Effects of the Merger 2 1.4 Directors and Officers of the Surviving Corpo |
|
| March 18, 2013 |
EX-99.1 4 d503688dex991.htm EX-99.1 Exhibit 99.1 Contacts: Scott Solomon Kerry McAnistan Vice President Investor Relations Assistant Sharon Merrill Associates, Inc. Palomar Medical Technologies, Inc. 617.542.5300 781-993-2411 [email protected] [email protected] Cynosure Signs Definitive Agreement to Acquire Palomar Medical Technologies • Creates One of World’s Premier Aesthetic Laser |
|
| March 18, 2013 |
THOMSON REUTERS STREETEVENTS | EX-99.2 9 d503633dex992.htm EX-99.2 Exhibit 99.2 1 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us © 2013 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. ‘Thomson Reuters’ and the Thomson Reuters logo are registered trademarks |
|
| March 18, 2013 |
AMENDMENT NO. 1 TO AMENDED AND RESTATED RIGHTS AGREEMENT EX-4.1 3 d503633dex41.htm EX-4.1 Exhibit 4.1 EXECUTION VERSION AMENDMENT NO. 1 TO AMENDED AND RESTATED RIGHTS AGREEMENT This AMENDMENT NO. 1 TO AMENDED AND RESTATED RIGHTS AGREEMENT (this “Amendment”) is entered into as of March 17, 2013, between Palomar Medical Technologies, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC, a limited liability trust c |
|
| March 18, 2013 |
EX-2.1 Table of Contents Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among CYNOSURE, INC., COMMANDER ACQUISITION CORP. and PALOMAR MEDICAL TECHNOLOGIES, INC. Dated as of March 17, 2013 Table of Contents TABLE OF CONTENTS ARTICLE I THE MERGER 1 1.1 Effective Time of the Merger 1 1.2 Closing 1 1.3 Effects of the Merger 2 1.4 Directors and Officers of the Surviving Corporation 2 ARTICLE II CONVER |
|
| March 18, 2013 |
CYNOSURE, INC. EMPLOYMENT AGREEMENT EX-10.3 3 d503688dex103.htm EX-10.3 Exhibit 10.3 CYNOSURE, INC. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of the 17th day of March, 2013 by and between Cynosure, Inc., a Delaware corporation (the “Company”) and Joseph P. Caruso (“Executive”). BACKGROUND A. Palomar Medical Technologies, Inc. (“Palomar”), the Company, and a wholly owned subsidiary |
|
| March 18, 2013 |
EX-10.2 5 d503633dex102.htm EX-10.2 Exhibit 10.2 BUYER STOCKHOLDER AGREEMENT This Stockholder Agreement (this “Agreement”), dated as of March 17, 2013, is entered into by and between Palomar Medical Technologies, Inc., a Delaware corporation (the “Company”), and the undersigned stockholder (“Stockholder”) of Cynosure, Inc., a Delaware corporation (the “Buyer”). WHEREAS, concurrently with the execu |
|
| March 18, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2013 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 18, 2013 |
EX-2.1 2 d503688dex21.htm EX-2.1 Table of Contents Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among CYNOSURE, INC., COMMANDER ACQUISITION CORP. and PALOMAR MEDICAL TECHNOLOGIES, INC. Dated as of March 17, 2013 Table of Contents TABLE OF CONTENTS ARTICLE I THE MERGER 1 1.1 Effective Time of the Merger 1 1.2 Closing 1 1.3 Effects of the Merger 2 1.4 Directors and Officers of the Surviving Corpo |
|
| March 18, 2013 |
EX-10.4 7 d503633dex104.htm EX-10.4 Exhibit 10.4 Paul S. Weiner 16 Mayo Road Wellesley, MA 02482 Dear Mr. Weiner: Reference is made to your employment agreement with Palomar Medical Technologies, Inc. (the “Company”) dated July 1, 2001, as amended by amendments dated May 19, 2010 and May 15, 2012 (together, the “Employment Agreement”). As you know, in connection with the proposed merger of the Com |
|
| March 18, 2013 |
CYNOSURE, INC. EMPLOYMENT AGREEMENT EX-10.3 3 d503688dex103.htm EX-10.3 Exhibit 10.3 CYNOSURE, INC. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of the 17th day of March, 2013 by and between Cynosure, Inc., a Delaware corporation (the “Company”) and Joseph P. Caruso (“Executive”). BACKGROUND A. Palomar Medical Technologies, Inc. (“Palomar”), the Company, and a wholly owned subsidiary |
|
| March 18, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2013 Cynosure, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-51623 04-3125110 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 18, 2013 |
THOMSON REUTERS STREETEVENTS | EX-99.3 Exhibit 99.3 1 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us © 2013 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. ‘Thomson Reuters’ and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its |
|
| March 18, 2013 |
THOMSON REUTERS STREETEVENTS | Exhibit 99.3 1 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us © 2013 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. ‘Thomson Reuters’ and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliat |
|
| March 18, 2013 |
Cynosure Signs Definitive Agreement to Acquire Palomar Medical Technologies EX-99.3 10 d503633dex993.htm EX-99.3 Exhibit 99.3 Cynosure Signs Definitive Agreement to Acquire Palomar Medical Technologies March 18, 2013 Forward-Looking Statements With the exception of the historical information contained in this presentation, the matters described herein contain forward-looking statements, including, but not limited to, statements relating to long-term growth and profitabili |
|
| March 18, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2013 PALOMAR MEDICAL TECHNOLOGIES, INC. |
|
| March 8, 2013 |
SUBSIDIARIES OF THE REGISTRANT EX-21.1 3 d444106dex211.htm EX-21.1 SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 SUBSIDIARY JURISDICTION OF INCORPORATION Cynosure France France Cynosure GmbH Germany Cynosure K.K. Japan Cynosure UK Ltd. United Kingdom Cynosure Spain S.L. Spain Cynosure Securities Corporation United States Suzhou Cynosure Medical Devices Company Ltd. China Cynosure Mexico Mexico Cynosure Korea Limited Korea |
|
| March 8, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K 10-K 1 d444106d10k.htm FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from |
|
| March 8, 2013 |
Exhibit 10.7 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. EXCLUSIVE DISTRIBUTION AGREEMENT (for Smartlipo MPX and SLT II Laser System) THIS AGREEMENT is made by and between El. En. S.p.A., a company organized under the laws of Italy whose address is Via Baldanzese 17, 50041 Calenzano, Firenze, Italy (hereafter r |
